CHARACTERISTICS and OUTCOMES of SARS-COV-2 BREAKTHROUGH INFECTIONS among DOUBLE and TRIPLE VACCINATED PATIENTS with INFLAMMATORY RHEUMATIC DISEASES
Annals of the Rheumatic Diseases
; 81:119, 2022.
Article
in English
| EMBASE | ID: covidwho-2009038
ABSTRACT
Background:
SARS-CoV-2 vaccines offer the most effective way to reduce the risk of severe COVID-19. Recent data indicate sufficient immune response after vaccination in most patients with infammatory rheumatic diseases (IRD) on immunomodulatory treatments.Objectives:
To investigate the clinical profile of SARS-CoV-2 breakthrough infections among double and triple vaccinated patients with IRD.Methods:
Data from the German COVID-19-IRD registry, collected by treating rheumatologists between February 2021 and January 2022 were analysed. Patients double or triple vaccinated against COVID-19 ≥14 days prior to proven SARS-CoV-2 infection were identifed, and type of IRD, vaccine, immunomodulation, comorbidities and outcome of the infection were compared with 737 unvac-cinated IRD-patients with COVID-19.Results:
In total, 271 cases of breakthrough infections were reported, 250 patients (91%) had received two doses of vaccines, 21 (9%) patients three. More than 70% of the patients received Pfzer/Biontech vaccine for the frst, second and third vaccination. The median time from second/third vaccine dose to infection was 148 days (range 14-302) days. Most of the patients were diagnosed with infamma-tory joint diseases (Table 1). Most of the patients were treated with methotrexate (Table 1). The use of Januskinase inhibitors(i) was more frequently reported in double vaccinated patients (10.4% vs 4.8%), whereas tumor necrosis (TNF)i were reported more often in triple vaccinated patients (33.3% vs. 22.8). Hospitalisation rate was higher in unvaccinated IRD-patients than in vaccinated ones, while fatality rate was similar in unvaccinated and double vaccinated patients. Although the rate of comorbidities and median age were higher in triple-vaccinated patients, infected patients showed a lower rate of hospitalisation, neither COVID-19 related complications, nor the need of oxygen treatment or death.Conclusion:
In this cohort of triple-vaccinated IRD patients no fatal courses and no COVID-19 related complications were reported, although median age and rate of comorbidities were higher compared to double-vaccinated and unvacci-nated patients. These results support the general recommendations to reduce the risk of severe COVID-19 disease by administering three doses of vaccine, especially in patients with older age, presence of comorbidities, and on immuno-modulatory treatment.
endogenous compound; methotrexate; tumor necrosis factor; vaccine; aged; arthropathy; breakthrough infection; cancer patient; cohort analysis; comorbidity; complication; conference abstract; controlled study; coronavirus disease 2019; disease registry; drug therapy; female; hospitalization; human; immunomodulation; major clinical study; male; mortality rate; nonhuman; outcome assessment; oxygen therapy; rheumatic disease; rheumatologist; Severe acute respiratory syndrome coronavirus 2; tumor necrosis; vaccination; vaccinee
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Annals of the Rheumatic Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS